Durham pharma lands $2.5M from NIH to target Alzheimer’s disease


A Durham pharmaceutical company has landed a $2.5 million award from the federal government to advance its treatment for Alzheimer's disease.

Previous Prime Therapeutics looks to sublease Eagan headquarters
Next Denver housing market approaching balance for first time in 16 years, say Realtors